BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 19765945)

  • 1. [HPV immunization for the prevention of cervical cancer].
    Mougin C; Bourgault-Villada I; Coursaget P
    Presse Med; 2009 Dec; 38(12):1750-68. PubMed ID: 19765945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cervix carcinoma--Austrian Vaccination Committee recommends HPV vaccination].
    Six L; Joura EA
    Wien Med Wochenschr; 2007; 157(5-6):130-2. PubMed ID: 17427010
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF
    Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
    Hantz S; Alain S; Denis F
    Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [What should be known for the introduction of an HPV vaccine?].
    Muñoz N; Jacquard AC
    Presse Med; 2008 Oct; 37(10):1377-90. PubMed ID: 18786806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
    Schwarz TF
    Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPV vaccines: preclinical development.
    Gissmann L
    Arch Med Res; 2009 Aug; 40(6):466-70. PubMed ID: 19853186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cervical cancer vaccine development.
    Frazer IH
    Sex Health; 2010 Sep; 7(3):230-4. PubMed ID: 20719210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vaccination perspective against human papillomavirus and consequences for the screening of uterine cervical neoplasm].
    Delvenne P
    Bull Mem Acad R Med Belg; 2007; 162(10-12):483-8; discussion 489-90. PubMed ID: 18557390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introducing human papillomavirus vaccines - questions remain.
    Paavonen J; Lehtinen M
    Ann Med; 2008; 40(3):162-6. PubMed ID: 18382882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
    Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
    Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
    David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
    Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
    Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
    J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus vaccine and cervical cancer prevention: practice and policy implications for pharmacists.
    McIntosh J; Sturpe DA; Khanna N
    J Am Pharm Assoc (2003); 2008; 48(1):e1-13; quiz e14-7. PubMed ID: 18192123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of cervical cancer: where immunology meets diagnostics.
    Meijer CJ; Heideman DA; Berkhof H; Snijders PJ
    Immunol Lett; 2009 Feb; 122(2):126-7. PubMed ID: 19100775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant vaccines for the prevention of human papillomavirus infection and cervical cancer.
    Palmer KE; Jenson AB; Kouokam JC; Lasnik AB; Ghim SJ
    Exp Mol Pathol; 2009 Jun; 86(3):224-33. PubMed ID: 19454268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Human papillomavirus and carcinoma of the cervix vaccines against the human papillomavirus-promise of an efficacious prevention].
    Kohl I
    Klin Mikrobiol Infekc Lek; 2006 Jun; 12(3):91-7. PubMed ID: 17051469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.